Effective and cheap removal of leukocytes and platelets from Plasmodium vivax infected blood by Sriprawat, Kanlaya et al.
BioMed  Central
Page 1 of 7
(page number not for citation purposes)
Malaria Journal
Open Access Methodology
Effective and cheap removal of leukocytes and platelets from 
Plasmodium vivax infected blood
Kanlaya Sriprawat†1, Supaporn Kaewpongsri†1, Rossarin Suwanarusk2, 
Mara L Leimanis1, Usa Lek-Uthai3, Aung Pyae Phyo1, Georges Snounou2,4,5,6, 
Bruce Russell*2,7, Laurent Renia2 and François Nosten1,8,9
Address: 1Shoklo Malaria Research Unit, Mae Sod, PO Box 46, Tak 63110, Thailand, 2Singapore Immunology Network (SIgN), IMMUNOS 
Building 3-4, BIOPOLIS, 8A Biomedical Grove, 138648, Singapore, 3Department of Parasitology and Entomology, Faculty of Public Health, 
Mahidol University, 420/1 Rajvithi Road, Rajthewee, Bangkok 10400, Thailand, 4Département de Parasitologie, INSERM UMR S 945, Hôpital 
Pitié-Salpêtrière, Paris, France, 5Faculté de Médecine Pitié-Salpêtrière, Université Pierre et Marie Curie, 4 place jussieu, 75005, Paris, France, 
6Department of Microbiology, Laboratory of Molecular and Cellular Parasitology, Faculty of Medicine, National University of Singapore, 5 Science 
Drive 2, 117597, Singapore, 7Nano Biomechanics Laboratory, Division of Bioengineering and Department of Mechanical Engineering, National 
University of Singapore, 10 Kent Ridge Crescent, 119260, Singapore, 8Medicine, Nuffield Department of Clinical Medicine, University of Oxford, 
CCVTM, Oxford, OX3 7LJ, UK and 9Faculty of Tropical Medicine, Mahidol University, 420/6 Rajvithi Road, Bangkok, 10400, Thailand
Email: Kanlaya Sriprawat - poo@shoklo-unit.com; Supaporn Kaewpongsri - jum@shoklo-unit.com; 
Rossarin Suwanarusk - rossarin_suwanarusk@immunol.a-star.edu.sg; Mara L Leimanis - mara@tropmedres.ac; Usa Lek-
Uthai - phulu@mahidol.ac.th; Aung Pyae Phyo - aungpyaephyo@shoklo-unit.com; Georges Snounou - snounou@mnhn.fr; 
Bruce Russell* - bruce_russell@immunol.a-star.edu.sg; L a u r e n tR e n i a-r e n i a _ l a u r e n t @ i m m u n o l . a - s t a r . e d u . s g ;  
François Nosten - francois@tropmedres.ac
* Corresponding author    †Equal contributors
Abstract
Background: Investigations of Plasmodium vivax are restricted to samples collected from infected
persons or primates, because this parasite cannot be maintained in in vitro cultures. Contamination
of P. vivax isolates with host leukocytes and platelets is detrimental to a range of ex vivo and
molecular investigations. Easy-to-produce CF11 cellulose filters have recently provided us with an
inexpensive method for the removal of leukocytes and platelets. This contrasted with previous
reports of unacceptably high levels of infected red blood cell (IRBC) retention by CF11. The aims
of this study were to compare the ability of CF11 cellulose filters and the commercial filter
Plasmodipur at removing leukocyte and platelet, and to investigate the retention of P. vivax IRBCs
by CF11 cellulose filtration.
Methods and Results: Side-by-side comparison of six leukocyte removal methods using blood
samples from five healthy donor showed that CF11 filtration reduced the mean initial leukocyte
counts from 9.4 × 103 per μl [95%CI 5.2–13.5] to 0.01 × 103 [95%CI 0.01–0.03]. The CF11 was
particularly effective at removing neutrophils. CF11 treatment also reduced initial platelet counts
from 211.6 × 103 per μl [95%CI 107.5–315.7] to 0.8 × 103 per μl [95%CI -0.7–2.2]. Analysis of 30
P. vivax blood samples before and after CF11 filtration showed only a minor loss in parasitaemia (≤
7.1% of initial counts). Stage specific retention of P. vivax IRBCs was not observed.
Conclusion: CF11 filtration is the most cost and time efficient method for the production of
leukocyte- and platelet-free P. vivax-infected erythrocytes from field isolates.
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Background
The emergence of drug resistance[1] and the renewed
awareness of severity in vivax malaria[2] is spurring efforts
to better understand this important pathogen. However,
exploiting the recently published genome[3] and tran-
scriptome[4] of Plasmodium vivax still relies on the use of
infected blood samples collected from patients or experi-
mentally infected simians, because it is not yet possible to
continuously culture this parasite.
Removal of leukocytes and other components from
infected blood samples is an important prerequisite for a
number of investigations. Sequencing the parasite's
genome can be significantly hampered by the relatively
large quantities of host DNA present in white blood cells.
Furthermore, it has been shown that the leukocytes
present in samples can phagocytise, damage and poten-
tially destroy malaria parasites under ex vivo investiga-
tions[5,6]. Antimicrobial and biochemical studies of
infectious diseases may also be confounded by the signif-
icant metabolic activity of leukocytes in the sample of
interest. Recently, the bioethical regulations in many
countries mandate the removal of human leukocytes from
infected blood samples, before transfer to other countries,
in order to curb the possibility of unauthorized human
genomic research. Other blood components are best
removed from the collected blood before in vitro testing.
Platelets often bind to and degranulate on contact with
infected red blood cells (IRBCs) adversely affecting the
parasite's ex vivo development[7].
The wide range of leukocyte removal techniques that have
been developed since the 1950s, are mostly based on dif-
ferential centrifugation or on column filtration. Differen-
tial density centrifugation using sucrose solutions,
Percoll™, Nycodenz™, Ficoll™ and Lymphoprep™ (Greiner
Bio-One®) are particularly useful when a viable leukocyte
fraction is needed for subsequent immunological investi-
gations. However, these methods are particularly time
consuming. It is generally agreed that column filtration
methods are a more practical, rapid and effective method
for the removal of leukocytes [8-10]. Custom-made CF11
cellulose powder columns are significantly less expensive
than commercial filters such as Plasmodipur, however, it
has been reported that CF11 retains some IRBCs and in
particular mature asexual stages (trophozoite and sch-
izont) of P. vivax[11]. This contrasts with observations
made in recent studies where the use of CF11 cellulose fil-
ters with P. vivax samples did not result in a high loss of
mature stages after filtration [12-14].
The two aims of this study were to compare the efficacy of
leukocyte and platelet removal efficacy of CF11-based fil-
ters and of Plasmodipur, and to investigate whether stage
specific retention of P. vivax IRBCs occurs through CF11
cellulose filtration.
Methods
CF11 column construction
A 10 ml syringe (with the plunger removed) was tipped
with two 1 cm2 pieces of Grade 105 lens cleaning tissue
(Whatman®). The tissue was placed in the syringe so as to
cover the outlet lumen. Only syringes with a centred
rather than an offset outlet should be used. Ten ml of
loosely packed of CF11 cellulose powder (Whatman®)
were added to the syringe and then packed down to ~5.5
ml of packed cellulose. The tip and bottom of the syringe
were covered with aluminium foil, and then autoclaved.
When ready to use, the CF11 column was wetted with ~5
ml of isotonic phosphate buffered saline (PBS) solution
(without Ca2+ and Mg2+, pH 7.3).
Sample collection and processing
Due to the limited quantity of P. vivax IRBC healthy donor
blood was used for the initial side-by-side comparisons of
leukocytes and platelet removal methods. Ten ml of
whole blood were collected onto Lithium heparin from
five healthy donors by venepuncture. The whole blood
was centrifuged at 500 g for 5 min at room temperature.
The plasma supernatant was removed, but the buffy coat
fraction containing white blood cells (WBC) was added
back to the red blood cell (RBC) pellet. The RBC+WBC
mix from each donor was divided into five two ml por-
tions to which an equal volume of RPMI was added with
gentle mixing. The first tube was used as the control for
this study. The 2nd tube was centrifuged again as above
and the PBS supernatant and buffy coat carefully removed
from the packed RBC, this tube was the 'Buffy Coat
Removal' treatment. The 3rd tube was loaded into a five ml
syringe (the plunger removed) and mounted onto a Plas-
modipur™ filter (Euro-Diagnostica®) that was pre-rinsed
with a sterile PBS solution. Then gentle pressure was
applied to the syringe attached to the Plamodipur unit
and the filtered RBC/PBS (50% haematocrit) mix was col-
lected as the 'Plasmodipur' treatment. The 4th and 5th
tubes were added to PBS-wetted CF11 columns. The fil-
tered 4th sample was then collected as the 'CF11' treat-
ment. The filtered 5th sample was then added to another
unused CF11 column (pre-wetted with 5 ml of PBS). The
double filtered 5th sample was the 'CF11x2' treatment. In
addition to the above samples, three more healthy volun-
teers were recruited, and 8 ml of whole blood were col-
lected onto Lithium heparin. This blood was processed as
above and divided into four 2 ml samples. The first and
2nd tubes were processed as described above for the con-
trol and the 'CF11' treatments, respectively. The contents
of the 3rd tube were layered over 2 ml of Lymphoprep™
(Greiner Bio-One®) and centrifuged at 600 g for 20 min at
20°C, the leukocytes that banded at the interface wereMalaria Journal 2009, 8:115 http://www.malariajournal.com/content/8/1/115
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removed using a pipette, and the supernatant RBC frac-
tion was the 'Lymphoprep' treatment. The 4th tube was
processed as above for the 'Lymphoprep' treatment, but
then subsequently processed using the 'Plasmodipur'
treatment protocol described above. This final sample was
called the 'Lymphoprep and Plasmodipur' treatment.
Please note; unless specifically stated, the term 'CF11 fil-
tration' involved only a single CF11 filter, as opposed to
'CF11x2' which involved processing the sample using two
CF11 columns.
Complete blood counts of the control samples and the
suspensions obtained from the six treatments were con-
ducted using an Automated Hematology Analyzer (Model
pocH-100i, Sysmex Company) and by microscopic exam-
ination (x100 oil immersion) of Giemsa-stained thick
(250 fields) and thin smears (450 fields). The data from
the thin smears were used for differential lymphocyte
counts.
Effect of CF11 filtration on P. vivax isolates
Thick and thin smears were routinely made for the pre-
and post-CF11 filtration from each of the P. vivax isolates
collected, prior to ex vivo drug sensitivity testing at the
Shoklo Malaria Research Unit (SMRU), Mae Sod, Thai-
land. The pre- and post-CF11 filtration, thick and thin
smears from 30 randomly selected isolates collected dur-
ing 2008 were examined as follows. Parasitaemias were
determined from the number of IRBC per ten 100× oil
immersion fields (200 RBC per field) on the thin film. The
percentage of early (ring-like parasites with a single chro-
matin dot) and mature (amoeboid-like cytoplasm or pres-
ence of haemozoin) asexual stages was determined from
examining 200 parasites in the thick smears under 100×
oil immersion. Due to their very low numbers in the pre-
and post-filtration smears schizonts (parasites with 3 or
more chromatin dots and haemozoin) were combined
with the mature stage count. Gametocyte counts were too
low for statistical comparison.
Parametric analysis of non-paired data was calculated
using one-way analysis of variance. Non-parametric anal-
ysis of the paired data was performed using Wilcoxon or
Friedman's tests and post-hoc analysis using Dunn's test
(GraphPad Prism 5.01).
The clinical IRBC samples examined in this study were
collected under the following ethical guidelines in the
approved protocol OXTREC 027-05 (University of
Oxford, Centre for Clinical Vaccinology and Tropical
Medicine, UK)
Results and discussion
Cost- and time-effective removal of leukocytes
Plasmodipur filters were the most rapid method for the
filtration of donor blood with ~10 min per isolate as com-
pared to the ~20 min per isolate required for CF11 filtra-
tion. A Plasmodipur filtering unit costs ~50–55 USD
while a single CF11 column could be made at a total cost
of ~1 USD. The effectiveness of the two types of columns
to remove leukocytes and platelets from clinical blood
samples was then assessed (Figure 1A and 1B). Filtration
on CF11 and Plasmodipur reduced the mean initial leu-
kocyte counts from 9.4 × 103 per μl [95%CI 5.2–13.5] to
0.01 × 103  [95%CI 0.01–0.03] and 0.7 × 103  per  μl
[95%CI 0.4–1.8] respectively (Figure 1A). Filtration on
CF11 was particularly effective at removing platelets,
reducing the platelet count from 211.6 × 103  per  μl
[95%CI 107.5–315.7] to 0.8 × 103 per μl [95%CI -0.7–
2.2], a significantly greater platelet reduction when com-
pared to the mean platelet count of the Plasmodipur fil-
trate which was 14.0 × 103 per μl [95%CI -2.3–30.5]) (p =
0.02). Only by pre-processing the blood sample with
Lymphoprep prior to Plasmodipur filtration was it possi-
ble to reduce the mean leukocyte (0.3 × 103 per μl [95%CI
-1.1–1.8]) and platelet (0.0 × 103 per μl) contamination to
the same levels as that obtained by CF11 filtration. How-
ever, pre-treatment with Lymphoprep adds another 50
mins and a further ~8–9 USD to procedure, thus negating
the benefits of the relatively speedier Plasmodipur filtra-
tion. It was interesting to note that the composition of the
contaminating leukocytes in the suspension obtained
after Lymphoprep/Plasmodipur or CF11 filtration dif-
fered greatly. Leukocyte contamination in the Lympho-
prep/Plamodipur filtrate was predominantly neutrophils
(98%) with the remainder made up of lymphocytes and
basophils/monocytes (Figure 2). By contrast, no neu-
trophils were found in the CF11 filtrate where the small
number of contaminating leukocytes was either lym-
phocytes (59%) or basophils/eosinophils (41%). The spe-
cific removal of neutrophils by CF11 is of particular
advantage in ex vivo culture, where neutrophils readily
phagocytise maturing IRBCs [6].
The effect of CF11 filtration on P. vivax parasite numbers 
and stages
Filtration of P. vivax infected isolates resulted in median
parasitaemia change of -0.1% [IQR -0.3–0.03] (Figure
3A). This corresponds to a 7.14% reduction in IRBCs from
the initial median parasitaemia of 0.7% [IQR 0.38–1.12]
to a post filtration median parasitaemia of 0.65% [IQR
0.30–1.0] (p = 0.01). The magnitude of IRBC loss was
much less than the major losses previously reported for
CF11 filtration, namely from a starting parasitaemia of
0.37% to 0.18% in the filtrate for one sample and 0.43%
to 0.01% for the other, representing a 52% and 98%
reduction in parasitaemia respectively [11]. It was furtherMalaria Journal 2009, 8:115 http://www.malariajournal.com/content/8/1/115
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The comparative efficacy of six methods for removing leukocytes (A) and platelets (B) from five healthy donor blood samples  (repeated measures) prior to buffy coat removal Figure 1
The comparative efficacy of six methods for removing leukocytes (A) and platelets (B) from five healthy donor 
blood samples (repeated measures) prior to buffy coat removal. Leukocyte counts and platelet mean counts × 103μl 
of whole blood [+/-95% CI]; analysis by Automated Hematology Analyzer (Model pocH-100i, Sysmex Company).
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reported that CF11 selectively retained mature tropho-
zoites and schizonts, with only ring stages passing
through the CF11 unimpeded[11]. In this study we failed
to observe any selective retention of mature P. vivax stages,
the median pre- and post-filtration composition of late
stages in the P. vivax samples was 17% and 19% respec-
tively. The median change in the composition of late
stages pre- and post-filtration was an increase of 1.0%
[IQR -4.2 to 4.2] (p = 0.06) (Figure 3B). This is consistent
with our experience with routine use of CF11 filtration of
P. vivax isolate where the loss of mature forms were not
noted[12,13,15], and where CF11 filtration did not effect
P. vivax maturation of early or late stage trophozoites.
It should be noted that equally satisfactory removal of leu-
kocytes and platelets, with little loss of parasites, were
obtained when the PBS solution was used to wash and
resuspend the blood and the CF11 columns was replaced
by RPMI or McCoy's 5A medium (GIBCO®)
Conclusion
Custom-made CF11 filtration provides a cost effective
method for the removal of leukocytes from P. vivax clini-
cal isolates. The small, non stage specific, reduction in par-
asitaemia due to CF11 filtration has done little to hamper
its application to a range of recent P. vivax studies [12-
14,16], notably the recent report on the P. vivax transcrip-
tome[4]. Although the report of high parasite losses due
to CF11 filtration were only based on two samples [11],
the magnitude of the losses was substantial. It is unlikely
that variations in the quality of the CF11 powder account
for the discrepancy between this observation and ours.
The composition of the buffers used to resuspend and
wash the blood samples and the column might, on the
other hand, substantially modify the binding properties
of the CF11 powder to different cell types. This is evident
from the first report of P. vivax retention by CF11 [17]
where the mere addition of 2 mM EDTA improved the
recovery of IRBCs. Furthermore, in our experience the
quantity of CF11 powder per ml of whole blood, the
degree of column compaction, as well as the amount and
extent of washing, influence the efficacy of the protocol. If
the 'leukocyte free' status of the IRBC preparation is a pri-
ority, we recommend the CF11x2 protocol (Figure 1A).
Notwithstanding the detailed description we provide for
our protocol, we strongly recommend that the procedure
be validated on test samples before its routine adoption.
An additional benefit of WBC and platelet filtration, irre-
spective of the method chosen, is that it aids in the micro-
scopic examination of thick films. Thick films made from
filtered isolates produce clear 'noise-free' thick films (Fig-
ure 4). This may also be crucial in the successful develop-
ment of digital recognition software for automating
parasite counts [18].
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Comparison of leukocyte composition of five healthy donor  blood samples before and after treatment with Lymphoprep  and Plasmodipur and CF11 methods Figure 2
Comparison of leukocyte composition of five healthy 
donor blood samples before and after treatment 
with Lymphoprep and Plasmodipur and CF11 meth-
ods. Leukocyte counts are expressed as Mean Count per 
250 Thick Films (100× oil immersion).
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The effect of CF11 filtration on the parasitaemia (A) and developmental stage composition (B) of 30 Thai Plasmodium vivax iso- lates Figure 3
The effect of CF11 filtration on the parasitaemia (A) and developmental stage composition (B) of 30 Thai Plas-
modium vivax isolates. The effect of filtration is expressed as a change in the percentage parasitaemia (IRBC per 10 thin film 
fields at 100× oil immersion) or percentage mature P. vivax erythrocytic stages [(mature stages/(early stages + mature 
stages)*100)] relative to the blood stages prior to CF11 filtration (no change denoted by the red broken line).
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The effect of CF11 filtration on thick and thin Giemsa stained films Figure 4
The effect of CF11 filtration on thick and thin Giemsa stained films. Photomicrographs of thick (A&C) and thin 
(B&D) films before and after CF11 filtration (100× oil immersion, Scale bar = 20 μm).Publish with BioMed Central    and   every 
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